Efficacity of ternidazole-neomycin sulfate-nystatin and prednisolone association in syndromic management of vaginitis in low and middle incomes countries

Authors

  • Dehi Boston Mian Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire
  • Vedi Andre Serges Loue Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire
  • Aya Virginie Angoi Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire
  • Alexis Yao Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire
  • Akinloye Sofia Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire
  • Koffi N' guessan Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire
  • Serge Boni Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d'Ivoire

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20220543

Keywords:

Vulvovaginitis, Mycobacterial analysis, Ternidazole-neomycin sulfate-nystatin-prednisolone

Abstract

Background: Vaginitis is a frequent and treated based on clinical evaluation in our countries in absence of microbiological laboratories. Evaluate the effectiveness of the management of vaginitis by ternidazole, neomycin sulfate, nystatin, prednisolone association.

Methods: A five-month prospective study was carried out in three health facilities in Abidjan. Two-hundred and thirty-three patients with clinical signs of vaginitis were included after signed consent. Pregnant and breast-feeding patients, hypersensitivity or idiosyncrasy to ternidazole, neomycin sulfate, nystatin, prednisolone association were not included. Patients were divided into reference group (n=200) for which a microbiological analysis of vaginal secretions was carried out 2-4 days before treatment and control group (n=33) for which treatment was initiated straightaway. Evaluation criteria were clinical symptoms, microbiological balance carried out 10 to 14 days after treatment and occurrence of side effects. Statistical tests used were Khi2 and exact Fisher test (p<0.05).

Results: Pathological leucorrhoea was differently observed in both group (p=0.001). During the follow-up visit, the persistence of symptoms was not different (p=0.99). This combination has demonstrated its efficacy in cases of Candida albicans vaginitis, bacterial vaginosis, trichomonas vaginalis vaginitis, and mixed vaginitis. A significantly improvement of symptoms (p=0.001) and low rate of biologically proven recurrence was observed in both groups. No allergic reactions linked was reported.

Conclusions: In our countries this therapeutic combination appears to be an option for treated mixed vaginitis in first intention without preliminary samples of vaginal secretions.

References

Larsen B. Vaginal Flora in Health and Disease. Clin Obstetr Gynecol. 2017;36:107-21.

Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med. 1998;13:335-46.

Murta EFC, Filho ACA. Barcelos ACM. Relation between vaginal and endocervical pH in pre-and post-menopausal women. Arch Gynecol Obstet. 2005;272 :211-3.

Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(1):4680-7.

Fettweis JM, Brooks JP, Serrano MG, Sheth NU, Girerd PH, Edwards DJ et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2017;160:2272-82.

Chen C, Song X, Wei W, Zhong H, Dai J, Lan Z et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017;8:875.

Pekmezovic M, Mogavero S, Naglik JR, Hube B. Host-pathogen interactions during female genital tract infections. Trends Microbiol. 2019;27;982-96.

Uchihashi M, Bergin IL, Bassis CM, Hashway SA, Chai D, Bell JD. Influence of age, reproductive cycling status, and menstruation on the vaginal microbiome in baboons (Papio anubis). Am J Primatol. 2015;77(5):563-78.

Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2012;66 :371-89.

Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PloS Biol. 2008;6:e280.

Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569;655-62.

Shao Y, Forster SC, Tsaliki E, Vervier K, Strang A, Simpson N et al. Stunted microbiota and opportunistic pathogen colonization in caesarean section birth. Nature. 2019;574;117-21.

Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55;205-11.

Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899-911.

Konje JC, Otolorin EO, Ogunniyi JO, Obisesan KA, Ladipo OA. The prevalence of Gardnerella vaginalis, Trichomonas vaginalis and Candida albicans in the cytology clinic at Ibadan, Nigeria. Afr J Med Med Sci. 1991;20(1):29-34.

Mirza NB, Nsanze H, D'Costa LJ, Piot P. Microbiology of vaginal discharge in Nairobi, Kenya. Br J Vener Dis. 1983;59(3):186-8.

Ray A, Gulati AK, Pandey LK, Pandey S. Prevalence of common infective agents of vaginitis. J Commun Dis. 1989;21(3):241-4.

Hart G. Factors associated with trichomoniasis, candidiasis and bacterial vaginosis. Int J STD AIDS. 1993;4(1):21-5.

Dan M, Kaneti N, Levin D, Poch F, Samra Z. Vaginitis in a gynaecology practice in Israel: Causes and risk factors. IMAJ. 2003;5:629-32.

Sobel JD. Vaginitis. N Eng J Med. 1997;337:1896-903.

Egan ME, Lipsky MS. Diagnosis of vaginitis. Am Fam Physician. 2000;62(5):1095-104.

Paladine HL, Desai UA. Vaginitis: Diagnosis and Treatment. Am Fam Physician. 2018;97(5):321-9.

ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstetr Gynecol. 2006;107(5):1195-1206.

Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):355-73.

Hainer BL, Gibson MV. Vaginitis. Am Fam Physician. 2011;83(7):807-15.

Schaaf VM, Perez-Stable EJ, Borchardt K. The Limited Value of Symptoms and Signs in the Diagnosis of Vaginal Infections. Arch Internal Med. 1990;150 :1929-33.

Eschenbach DA, Hillier SL. Advances in diagnostic testing for vaginitis and cervicitis. J Reprod Med. 1989;34(8):555-64.

Lin YP, Chen WC, Cheng CM, Shen CJ. Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis. Diagnostics (Basel). 2021;11(11):1996.

WHO-OMS 2008. Modules de formation pour la prise en charge syndromique des infections sexuellement transmissibles. 2008-ISBN9789242593402. Available at: https://www.who.int/reproductivehealth/publications/rtis/9789241593407/fr. Accessed on January 17, 2019.

Downloads

Published

2022-02-25

Issue

Section

Original Research Articles